Dimensional Fund Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$396M Buy
513,060
+13,516
+3% +$10.3M 0.08% 235
2025
Q4
$386M Buy
499,544
+448
+0.1% +$304K 0.08% 232
2025
Q3
$281M Sell
499,096
-20,341
-4% -$11.5M 0.06% 366
2025
Q2
$273M Sell
519,437
-51,750
-9% -$28.9M 0.06% 342
2025
Q1
$362M Sell
571,187
-15,838
-3% -$10.9M 0.09% 198
2024
Q4
$418M Buy
587,025
+16,961
+3% +$14.2M 0.1% 155
2024
Q3
$599M Sell
570,064
-16,498
-3% -$18.4M 0.15% 92
2024
Q2
$616M Sell
586,562
-2,391
-0.4% -$2.32M 0.16% 85
2024
Q1
$567M Sell
588,953
-4,569
-0.8% -$4.34M 0.15% 97
2023
Q4
$521M Sell
593,522
-25,744
-4% -$21.2M 0.15% 91
2023
Q3
$510M Buy
619,266
+6,442
+1% +$5.06M 0.17% 81
2023
Q2
$440M Sell
612,824
-20,684
-3% -$15.9M 0.14% 109
2023
Q1
$520M Sell
633,508
-1,080
-0.2% -$815K 0.18% 77
2022
Q4
$458K Sell
634,588
-15,819
-2% -$11.7M 0.14% 95
2022
Q3
$448M Buy
650,407
+18,501
+3% +$11.6M 0.17% 77
2022
Q2
$374M Buy
631,906
+46,757
+8% +$30.4M 0.13% 118
2022
Q1
$409M Buy
585,149
+82,651
+16% +$52.3M 0.13% 125
2021
Q4
$317M Buy
502,498
+98,968
+25% +$60.8M 0.1% 186
2021
Q3
$244M Buy
403,530
+83,276
+26% +$51.7M 0.08% 249
2021
Q2
$179M Buy
320,254
+70,107
+28% +$35.5M 0.06% 408
2021
Q1
$118M Buy
250,147
+13,304
+6% +$6.48M 0.04% 683
2020
Q4
$114M Buy
236,843
+11,978
+5% +$6.47M 0.04% 632
2020
Q3
$126M Buy
224,865
+8,460
+4% +$5.13M 0.05% 419
2020
Q2
$135M Buy
216,405
+7,195
+3% +$4.08M 0.06% 350
2020
Q1
$102M Buy
209,210
+2,510
+1% +$1.04M 0.05% 401
2019
Q4
$77.6M Sell
206,700
-2,192
-1% -$737K 0.03% 976
2019
Q3
$57.9M Buy
208,892
+12,301
+6% +$3.64M 0.02% 1253
2019
Q2
$61.5M Buy
196,591
+16,960
+9% +$5.65M 0.02% 1197
2019
Q1
$73.8M Sell
179,631
-3,806
-2% -$1.57M 0.03% 955
2018
Q4
$68.5M Buy
183,437
+5,971
+3% +$2.19M 0.03% 901
2018
Q3
$71.7M Buy
177,466
+5,605
+3% +$2.13M 0.03% 1042
2018
Q2
$59.3M Buy
171,861
+2,191
+1% +$685K 0.02% 1228
2018
Q1
$58.4M Buy
169,670
+2,053
+1% +$714K 0.02% 1164
2017
Q4
$63M Buy
167,617
+6,126
+4% +$2.48M 0.03% 1086
2017
Q3
$72.2M Buy
161,491
+633
+0.4% +$301K 0.03% 873
2017
Q2
$79M Buy
160,858
+1,564
+1% +$684K 0.04% 725
2017
Q1
$61.7M Buy
159,294
+4,039
+3% +$1.5M 0.03% 931
2016
Q4
$57M Sell
155,255
-900
-0.6% -$342K 0.03% 991
2016
Q3
$62.8M Buy
156,155
+14,767
+10% +$5.92M 0.03% 798
2016
Q2
$49.4M Buy
141,388
+415
+0.3% +$160K 0.03% 993
2016
Q1
$50.8M Buy
140,973
+4,526
+3% +$1.87M 0.03% 905
2015
Q4
$74.1M Buy
136,447
+7,316
+6% +$3.96M 0.05% 522
2015
Q3
$60.1M Buy
129,131
+1,926
+2% +$1.03M 0.04% 641
2015
Q2
$64.9M Buy
127,205
+5,032
+4% +$2.46M 0.04% 637
2015
Q1
$55.2M Buy
122,173
+1,008
+0.8% +$427K 0.03% 744
2014
Q4
$49.7M Buy
121,165
+6,226
+5% +$2.45M 0.03% 758
2014
Q3
$41.4M Sell
114,939
-14,276
-11% -$4.78M 0.03% 848
2014
Q2
$36.5M Buy
129,215
+906
+0.7% +$269K 0.03% 1000
2014
Q1
$38.5M Buy
128,309
+847
+0.7% +$261K 0.03% 867
2013
Q4
$35.1M Sell
127,462
-300
-0.2% -$86.3K 0.03% 914
2013
Q3
$40M Buy
127,762
+1,006
+0.8% +$265K 0.03% 698
2013
Q2
$28.5M Buy
+126,756
New +$29.5M 0.03% 900

Other funds holding REGN

Dimensional Fund Advisors's REGN Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 2.7% in Q1 2026, buying an estimated $10.3M and bringing the position to 513,060 shares worth $396M. The position accounts for 0.08% of the portfolio, ranked #235.

Dimensional Fund Advisors first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $616M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Dimensional Fund Advisors held 513,060 shares of Regeneron Pharmaceuticals worth $396M as of Q1 2026.
  • Dimensional Fund Advisors bought 13,516 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $10.3M.
  • Regeneron Pharmaceuticals made up 0.08% of Dimensional Fund Advisors's portfolio in Q1 2026, its #235 holding.
  • Dimensional Fund Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Dimensional Fund Advisors's Regeneron Pharmaceuticals position peaked at $616M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.